Buch, Englisch, 624 Seiten, Format (B × H): 216 mm x 276 mm, Gewicht: 450 g
A Companion to Braunwald's Heart Disease
Buch, Englisch, 624 Seiten, Format (B × H): 216 mm x 276 mm, Gewicht: 450 g
ISBN: 978-0-443-11986-6
Verlag: Elsevier Health Sciences
Part of the renowned Braunwald family of references, Heart Failure, 5th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald’s Heart Disease helps you make the most of new drug therapies, recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Drs. Douglas L. Mann, G. Michael Felker, and Scott D. Solomon, this award-winning reference is up to date, authoritative, and comprehensive—an essential resource for improving clinical outcomes in heart failure patients. - Focuses on a clinical approach to treating heart failure resulting from a broad variety of cardiovascular problems
- Covers key topics such as new drug therapies for HFrEF and HFpEF, novel devices, precision medicine, and HF prevention
- Reflects the most recent guidelines and protocols, including new updates to ACC, AHA, and HFSA guidelines
- Discusses the pathophysiological basis for the development and progression of heart failure
- Serves as a definitive resource to prepare for the ABIM’s Heart Failure board exam
- An eBook version is included with purchase. The eBook allows you to access all of the text, figures, and references, with the ability to search, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish after the publication date
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Section I: Basic Mechanisms of Heart Failure and Disease Progression
- Molecular and Cellular Basis for Heart Failure
- Molecular Signaling Mechanisms of the Renin-Angiotensin System in Heart Failure
- Adrenergic Receptor Signaling in Heart Failure
- Role of Innate Immune Activation in Heart Failure
- Natriuretic Peptides in Heart Failure
- Alterations in Systolic and Diastolic Ventricular Function in Heart Failure
- Alterations in Ventricular Structure: Role of Adverse Left Ventricular Remodeling and Reverse Remodeling in Heart Failure
- Alterations in the Sympathetic and Parasympathetic Nervous Systems in Heart Failure
- Alterations in the Peripheral Circulation in Heart Failure
- Alterations in Kidney Function Associated With Heart Failure
- Alterations in Skeletal Muscle in Heart Failure
- Alterations in Cardiac Metabolism in Heart Failure
- Mechanisms of Congestion in Heart Failure
Section II: Etiological Basis for Heart Failure
14. Epidemiology of Heart Failure
15. Heart Failure as a Consequence of Ischemic Heart Disease
16. Heart Failure as a Consequence of Dilated Cardiomyopathy
17. Restrictive Cardiomyopathies and Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
18. Amyloidosis as a Cause of Heart Failure
19. Heart Failure as a Consequence of Hypertrophic Cardiomyopathy
20. Heart Failure as a Consequence of Genetic Cardiomyopathy
21. Heart Failure as a Consequence of Valvular Heart Disease
22. Heart Failure as a Consequence of Congenital Heart Disease
23. Heart Failure as a Consequence of Viral and Nonviral Myocarditis
24. Heart Failure in Low- and Middle-Income Country Contexts
25. Heart Failure and Human Immunodeficiency Virus
26. Coronavirus Disease 2019 and Heart Failure
Section III: Clinical Assessment of Heart Failure
27. Clinical Evaluation of Heart Failure
28. Advanced Cardiac Imaging in Heart Failure: A Disease-Based Approach
29. Biomarkers in Precision Medicine
30. Hemodynamics in Heart Failure
Section IV: Therapy for Heart Failure
31. Disease Prevention in Heart Failure
32. Modulators of the Renin-Angiotensin-Aldosterone System and the Vasoactive Peptide System in Heart Failure
33. Beta-Adrenergic Blockers
34. Sodium-Glucose Cotransporter Inhibitors in Heart Failure
35. Acute Heart Failure
36. Additional Medical Therapies for Heart Failure Patients With Reduced Ejection Fraction
37. Management of Arrhythmias and Cardiac Implantable Electronic Devices in Heart Failure
38. Treatment of Heart Failure With Mildly Reduced or Preserved Ejection Fraction
39. Management of Heart Failure in Special Populations: Older Patients, Females, and Racial or Ethnic Minority Groups
40. Gene Therapy in Heart Failure
41. Neuromodulation in Heart Failure
42. Pulmonary Hypertension and the Right Ventricle
43. Heart Transplantation
44. Circulatory Assist Devices in Heart Failure
45. Cardio-Oncology and Heart Failure
46. Telemedicine in Heart Failure
47. Management of Comorbidities in Heart Failure
48. Implementation Science in Heart Failure
49. Decision-Making and Palliative Care in Advanced Heart Failure
